Company · founded 2010
Seres Therapeutics (United States)
Cambridge, United States · serestherapeutics.com
- Citations, last 5 years
- 672
- Works, last 5 years
- 61
- h-index
- 69
- Scientists listed
- 14
- Grants since 2016
- 6
Grants received
2024–2026 · research · R44
NX90: A Treatment for Overdose Caused by High Potency Opioids
Michael V. Voronkov · Seres Therapeutics (United States) · funded by National Institutes of Health
2024–2026 · research · R44
NX90: A Treatment for Overdose Caused by High Potency Opioids
Michael V. Voronkov · Seres Therapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R41
Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Peripheral Artery Disease
Ngan F. Huang · Seres Therapeutics (United States) · funded by National Institutes of Health
2019–2021 · research · R44
A Single Dose Long-Acting Non-Addictive Polymer Conjugate Formulation of Buprenorphine that Provides Immediate and Prolonged Analgesia for Post-Operative Pain
Randall W Moreadith · Seres Therapeutics (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Metabolically Reprogrammed Mesenchymal Stem Cells for Treating Osteoporosis
Dana Larocca · Seres Therapeutics (United States) · funded by National Institutes of Health
2018–2022 · research · R41
Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke
Andrew W Grande · Seres Therapeutics (United States) · funded by National Institutes of Health